Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis
Dermatol. Ther.
Patients with moderate-to-severe psoriasis (PsO) overwhelmingly remained on ixekizumab treatment for more than 2 years while participating in a PSP.
